Explore original, structured summaries for research and education.
Research profile
NAD+(Nicotinamide Adenine Dinucleotide)
NAD+(Nicotinamide Adenine Dinucleotide) is indexed as a Coenzyme research entry. Its current evidence category is (Nicotinamide Adenine Dinucleotide), and published discussion commonly places it within Longevity, Metabolic. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- 663.43 Da
- Chain length
- —
- Type
- Coenzyme
- Reported half-life
- 1-4 hours (intracellular)
C21H27N7O14P2Literature map
Research indications
Energy & Metabolism
- Cellular Energy Productionmost effective
- Metabolic Optimizationmost effective
- Exercise Performanceeffective
Anti-Aging
- DNA Repaireffective
- Sirtuin Activationeffective
- Cellular Senescence Reductionmoderate
Neurological
- Cognitive Enhancementmoderate
- Neuroprotectionmoderate
Evidence-gated guidance
Dosing Protocols
No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for NAD+(Nicotinamide Adenine Dinucleotide). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of NAD+(Nicotinamide Adenine Dinucleotide) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is NAD+(Nicotinamide Adenine Dinucleotide) approved for personal use?
This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- NAD+ and Sirtuins in Aging and DiseaseImai, S., Guarente, L. · Trends in Cell Biology · 2014
- Chronic Nicotinamide Riboside Supplementation Is Well-Tolerated and Elevates NAD+ in Healthy Middle-Aged and Older AdultsMartens, C.R., et al. · Nature Communications · 2018
- Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic WomenYoshino, M., et al. · Science · 2021
- NAD+ Metabolism and Its Roles in Cellular Processes During AgeingCovarrubias, A.J., et al. · Nature Reviews Molecular Cell Biology · 2021
- Efficacy of Oral NMN Supplementation on Glucose and Lipid Metabolism: A Systematic Review with Meta-Analysis of RCTsZhong, O., et al. · Journal of Translational Medicine · 2024
- A Randomized Placebo-Controlled Trial of Nicotinamide Riboside in Older Adults with Mild Cognitive ImpairmentOrr, M.E., et al. · GeroScience · 2024